Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.86 -0.60 (-5.24%)
Streaming Delayed Price Updated: 12:11 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,847,262
Open 11.51
Bid (Size) 10.85 (10)
Ask (Size) 10.87 (18)
Prev. Close 11.46
Today's Range 10.71 - 11.51
52wk Range 5.900 - 24.16
Shares Outstanding 88,140,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intellia (NTLA) Q2 Revenue Jumps 106%
Via The Motley Fool
Intellia Therapeutics Inc (NASDAQ:NTLA) Q2 2025 Earnings: Revenue Surpasses Estimates, Losses Narrower Than Expected
Intellia Therapeutics (NTLA) reported Q2 2025 revenue of $14.25M, beating estimates, with a narrower loss of $0.99 per share. Stock rose 2% pre-market amid strong clinical progress in CRISPR... 
Via Chartmill

Performance

YTD
-11.1%
-11.1%
1 Month
-2.3%
-2.3%
3 Month
+31.2%
+31.2%
6 Month
+7.2%
+7.2%
1 Year
-49.0%
-49.0%

More News

Read More
Earnings Scheduled For August 7, 2025
Via Benzinga
INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Via Benzinga
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews
Via Benzinga
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Via MarketBeat
Topics Economy Stocks
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
Via Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
Via Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
Via Investor's Business Daily
Assessing Intellia Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration
Via Benzinga
Topics Government
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
Via Chartmill
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip
Via Stocktwits
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Via Chartmill
HP Posts Downbeat Earnings, Joins SentinelOne, Best Buy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
What's going on in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Analysts Think These Stocks Could More Than Double in Value
Via MarketBeat
Topics World Trade

Frequently Asked Questions

Is Intellia Therapeutics, Inc. - Common Stock publicly traded?
Yes, Intellia Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Intellia Therapeutics, Inc. - Common Stock trade on?
Intellia Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Intellia Therapeutics, Inc. - Common Stock?
The ticker symbol for Intellia Therapeutics, Inc. - Common Stock is NTLA on the Nasdaq Stock Market
What is the current price of Intellia Therapeutics, Inc. - Common Stock?
The current price of Intellia Therapeutics, Inc. - Common Stock is 10.86
When was Intellia Therapeutics, Inc. - Common Stock last traded?
The last trade of Intellia Therapeutics, Inc. - Common Stock was at 08/08/25 12:11 PM ET
What is the market capitalization of Intellia Therapeutics, Inc. - Common Stock?
The market capitalization of Intellia Therapeutics, Inc. - Common Stock is 957.21M
How many shares of Intellia Therapeutics, Inc. - Common Stock are outstanding?
Intellia Therapeutics, Inc. - Common Stock has 957M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.